In May 2020, the Manhattan Associates, Inc. 2020 Equity Incentive Plan (the “2020 Plan”) was approved by our shareholders. The 2020 Plan provides for the grant of stock options, restricted stock, restricted stock units, and stock appreciation rights. Vesting conditions can be service-based or performance-based, or a combination of both. The number of shares subject to outstanding awards under the 2007 Stock Incentive Plan (the “2007 Plan”) that are forfeited or canceled or expire after the Effective Date, in accordance with the terms of the 2007 Plan, are counted as one share toward the 2020 Plan.

A maximum of 4,500,000 shares are available for grant under the amended 2020 Plan. Each stock option, stock appreciation right, restricted stock, or restricted stock unit granted is counted against the maximum share limitation as one share. Options and stock appreciation rights cannot have a term exceeding seven years. As of December 31, 2020, there were 4,526,518 shares available for issuance under the 2020 Plan. The 2020 Plan is administered by the Compensation Committee of the Board of Directors. The committee has the authority to interpret the provisions thereof.

The restricted stock awards contain vesting provisions that are 50% service based and 50% performance based for employee awards and 100% service based for non-employee members of the Board of Directors (“Outside Directors”). The employee awards have a four year vesting period, with the performance portion tied to annual revenue and earnings per share targets. The awards to Outside Directors have a one year vesting period. We recognize compensation cost for service-based restricted awards with graded vesting on a straight-line basis over the entire vesting period, with the amount of compensation cost recognized at any date at least equal to the portion of the grant-date value of the award that is vested at that date. For our performance-based restricted stock awards with graded vesting, we recognize compensation cost on an accelerated basis applying straight-line expensing for each separately vesting portion of each award.

In January 2012, in order to simplify equity grant administration, we changed the practice of granting restricted stock in favor of granting restricted stock units, or RSUs, which convert to our common stock upon vesting. There is no material difference between the grant of restricted stock and the grant of RSUs to either us or the recipients receiving the grants; however, in contrast to the granting of restricted stock, no stock will actually be issued under the granting of RSUs until the units vest. Currently, we do not grant stock options.

We present below a summary of changes in unvested units of restricted stock during 2020:

	Number of Units	Grant Date Fair Value
Outstanding at January 1, 2020	1,496,693	$50.67
Granted	535,387	77.20
Vested	(518,565)	52.48
Forfeited	(50,651)	57.96
Outstanding at December 31, 2020	1,462,864	$59.48

The Company recorded equity-based compensation expense related to restricted stock and RSUs (collectively “restricted stock awards”) of $33.4 million, $31.8 million, and $19.9 million in 2020, 2019 and 2018, respectively. The total fair value of restricted stock awards vested in 2020, 2019 and 2018, based on market value at the vesting dates was $52.2 million, $18.2 million, and $18.1 million, respectively. The weighted average grant-date fair value of RSUs granted during fiscal year 2020, 2019 and 2018 was $77.20, $49.48 and $51.72, respectively. As of December 31, 2020, unrecognized compensation cost related to unvested RSU totaled $47.0 million and is expected to be recognized over a weighted average period of approximately 2.2 years. In January 2017, we elected to recognize forfeitures of equity-based payments as they occur.

Included in RSU grants for the year ended December 31, 2020 are 303,375 units that have performance-based vesting criteria granted at target level for 2020 and performance adjustments above target level for 2019. The performance criteria are tied to our financial performance. As of December 31, 2020, the associated equity-based compensation expense has been recognized for the portion of the award attributable to the 2020 performance criteria.